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Double sensitization, systemic reactions, treatment with omalizumab, and high dose VIT
1

1

2

1

3

Gülden PAÇACI ÇETİN , İnsu YILMAZ , Murat TÜRK , Bahar ARSLAN , Sakine NAZİK BAHÇECİOĞLU 
1
Division of Immunology and Allergy, Department of Chest Diseases, Faculty of Medicine Erciyes University, Kayseri, Turkey
2
Division of Immunology and Allergy, Department of Chest Diseases, Kayseri City Training and Research Hospital, Kayseri, Turkey
3
Division of Immunology and Allergy, Department of Chest Diseases Atatürk Chest Disease and Thoracic Surgery Training and
Research Hospital, Ankara, Turkey
Received: 17.09.2021

Accepted/Published Online: 10.04.2022

Final Version: 10.08.2022

Background/aim: Venom immunotherapy (VIT) is the most effective treatment method to prevent recurrent systemic reactions
to Hymenoptera stings. In this study, the demographic characteristics of VIT patients, the success rates of VIT, the difficulties we
encountered during VIT, and solutions for these difficulties in our clinic were presented.
Materials and methods: We retrospectively analyzed patients with venom allergy who applied venom immunotherapy between 2013–
2020. Data on age, gender, Hymenoptera species with the first reaction, grade of the reaction, beekeeping history, skin prick and specific
IgE and component results, double sensitization, blood groups, and reactions with VIT and/or sting during built-up and maintenance
periods were recorded.
Results: A total of 73 patients were enrolled in the study. The median time from the first sting reaction to the application to the allergy
outpatient clinic was 12 (0.5–24) months. The first sting reaction of 38 (52.1%) of the patients was with honey bees, and 24 (32.9%)
were with wasps. Double positivity was present in 29 (40%) of the patients in prick results and 26 (36%) serologically. There was no
correlation between the severity of first reactions and Apis Mellifera or Vespula prick diameters (p = 0.643; r = –0.056; p = 0.462; r =
0.089, respectively). High-dose VIT was administered to 4 patients. Omalizumab has been used as an alternative agent to achieve the
maintenance dose in 2 patients with frequent systemic reactions during VIT.
Conclusion: Most patients were able to tolerate VIT. Double positivity is one of the most common difficulties before VIT. In patients
who develop systemic reactions in the VIT maintenance phase, a maintenance dose increase should be considered in the maintenance
phase. Adding omalizumab does not seem to be a permanent solution in patients who develop a severe systemic reaction.
Key words: Allergy, venom immunotherapy, Apis Mellifera, Vespula, double sensitization, omalizumab

1. Introduction
A Hymenoptera sting is a common condition in society,
and 56%–94% of people are stung at least once in their
lifetime [1]. Allergic reactions to Hymenoptera venom
are often extensive local reactions at the injection site and
systemic reactions. Large local reaction (LLR) was defined
as painful swelling and erythema exceeding 10 cm in
diameter lasting longer than 24 h, limited to the skin and
subcutaneous tissue [2]. Systemic sting reactions (SSR) may
occur with multiple organ involvement and anaphylaxis;
it can also be seen in milder forms such as urticaria and/
or angioedema [3]. The prevalence of systemic reactions
in European epidemiological studies is between 0.3% and
7.5% in adults, and broad local reactions are 2%–4%–
26.4% in the population [4,5]. Severe reactions can be life-

threatening and mortal. Patients diagnosed with venom
allergy should carry emergency kits containing adrenaline
auto-injector, H1 antihistamines, and corticosteroids
against the risk of anaphylaxis.
Venom immunotherapy (VIT) is the most effective
treatment method to prevent recurrent systemic
reactions [6,7]. It is effective in 77%–84% of the patients
undergoing immunotherapy (IT) with honey bee venom
and in 91%–96% of patients receiving immunotherapy
with wasp venom [8]. Although VIT success is high,
some difficulties may be encountered before IT and in
the IT process. Detection of SPT (skin prick test) and/
or specific immunoglobulin E (sIgE) double positivity
against different species, especially in persons stung with
unknown bee species, leads the clinician to make further
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examinations and make the decision more carefully when
selecting the proper venom extract [9–11]. Another
difficulty is serious systemic reactions that can occur
during the build-up and maintenance doses of IT. VIT is
restarted with dose reduction, especially in severe systemic
reactions seen with VIT during the build-up phase. Still,
despite this, VIT can be continued with omalizumab to
suppress the secondary systemic effects related to VIT and
continue IT in patients who have anaphylaxis after VIT. In
cases with severe anaphylaxis in the maintenance phase,
high-dose VIT should be considered.
In this study, the demographic characteristics of VIT
patients, the success rates of VIT, and the difficulties we
encountered during VIT in our clinic were discussed
together with the current literature.
2. Materials and methods
This study was conducted by examining the data of
2013–2020 in Erciyes University Immunology and Allergy
Diseases Clinic, retrospectively. The data of patients who
had an SSR after a honey bee or wasp sting and who
started VIT in line with the guideline recommendations
were analyzed. Data on age, gender, bee species with the
first reaction, grade of the reaction, beekeeping history,
skin prick and specific IgE and component results, blood
groups, and reactions with IT and/or bee sting during
built-up and maintenance periods were recorded.
In our clinic, conventional VIT was applied to all
patients with the same allergen extract (Alutard® SQ, ALKAbelló, Denmark). The maintenance phase was reached
at approximately 16 weeks. However, in patients who
experienced a systemic reaction in the build-up phase, the
time to reach the maintenance phase was prolonged, since
step-downs were made according to the severity of the
reaction. At the end of the second year, the dose intervals
were increased to 6 weeks, and 8 weeks after 3 years, in
patients who did not experience any systemic reactions
at the beginning and maintenance and we thought that
there would be no compliance problems. The built-up
phase was started with 20 U-SQ/mL, and the dose was
increased up to the standard maximum maintenance dose
of 100,000 U-SQ/mL. Routine use of antihistamines was
recommended as a premedication before VIT in the builtup phase. All doses were administered in the equipped
immunotherapy room under the supervision of a doctor.
In cases where the systemic reaction was observed in the
built-up phase, a dose reduction was made according
to the reaction intensity, and it was restarted from the
recommended previous doses. VIT was continued along
with omalizumab treatment in some of the patients whose
systemic reaction continued. In the case of a systemic
reaction with VIT and/or bee sting in the maintenance
phase, the dose was reduced by 2–4 steps, and the
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maintenance dose was increased up to 150,000 U-SQ/
mL. Underlying factors such as double-sensitization,
high tryptase levels, and mastocytosis that may affect the
success of VIT were investigated in all patients.
Ring and Messmer Anaphylaxis Grading Scale were
used to grade the reaction [12].
2.1. Skin prick test (SPT)
Allergen extract drops were first applied to the forearm.
This was followed by pricking the skin with a special
lancet (Heinz Herenz Hamburg, Germany). A distance of
more than 2 cm was ensured between different allergen
extracts. At the end of 20 min, the induration size that
was ≥3 mm larger than the size of the induration resulting
from a negative control was considered positive. Apis
Mellifera and Vespula SPT extract (ALK Vespula spp. 100
μg/mL, ALK Apis Mellifera 100 μg/mL, ALK Vespula spp.
300 μg/mL, ALK Apis Mellifera 300 μg/mL) were used
to conduct the test in all patients. Skin prick tests were
performed with bee venom extracts at a concentration
of 100 μg/mL, if it was negative, the bee venom extract
concentration dose was increased to 300 μg/mL (Figure 1).
Before starting VIT in patients who developed a systemic
reaction with skin prick test at these concentrations, VIT
was started with lower concentrations than the current
starting dose. The test was performed by an experienced
nurse and doctor at the clinic. All patients had vascular
access before SPT.
2.2. Sample measurement
The serum Apis Mellifera specific IgE and Vespulaspecific IgE levels were determined with the ELISA
method (ThermoFisher Scientific ImmunoCAP, U.S.).
Classification in this method is class 0: < 0.35 kU/L (no
allergy), class 1: 0.35–0.7 kU/L (low positive), class 2:
0.70–3.5 kU/L (positive), class 3: 3.50–17.5 kU/L (strong
positive), class 4: 17.5–50 kU/L (high positive), class 5:
50–100 kU/L (very high positive), and class 6: ≥100 kU/L
(extremely positive)[13].
2.3. Statistical analysis
The data analysis was performed by SPSS statistical
software (SPSS Inc. Chicago, Illinois) version 22. The
central tendency and dispersion of numerical data were
shown as mean ± standard deviation (SD) for normally
distributed data and median (interquartile range) for the
nonnormally distributed data. The analysis of normally
distributed data was performed with the Kolmogorov
Smirnov test. Comparisons between independent
groups were performed with Pearson chi-square test for
categorical variables and with independent sample t-test,
Mann Whitney U test or Kruskal Wallis for continuous
variables. Spearman’s correlation was used to detect the
relationship between parameters. P-value < 0.05 was
considered significant.

PAÇACI ÇETİN et al. / Turk J Med Sci

Figure 1. A schematization for SPT. SPT: Skin prick test

3. Results
The general characteristics of 73 patients who underwent
VIT are shown in Table 1. Thirty-eight (52%) of the
patients were female, and the mean age of all patients was
43 ± 12.9 years. Seventeen (23.3%) patients were dealing
with beekeeping either professionally or as a hobby. The
first sting reaction of 38 (52.1%) of the patients was with
honey bees, and 24 (32.9%) were with wasps. Eleven
(15.1%) patients did not know the type of Hymenoptera
with which the first reaction was experienced. The median
time from the first sting reaction to the application to
the allergy outpatient clinic was 12 (0.5–24) months. The
reaction severity was made according to the Ring and
Messmer classification; a mild reaction was observed in
6 (8.2%) of the patients, while 67 (91.2%) experienced a
moderate and severe reaction. At least one of the pricks
and/or specific IgE results of all patients had a positive
Apis Mellifera or Vespula. Double positivity was present in
29 (40%) of the patients in prick results, in 26 (36%) of the
patients serologically, and in 41 (56%) of the patients in at
least one of these results.
Since beekeeping constitutes the risk group for honey
bee anaphylaxis, the characteristics of those engaged in
beekeeping and those who do not have been compared.
The general characteristics of the patients engaged in
beekeeping as a hobby or professionally and those who do
not are shown in Table 2. The first reaction of 15 (88%) of

17 patients who are beekeeping developed against honey
bees. Four out of 6 patients who started VIT with Grade
1 reaction were beekeepers. Although the time from the
first sting reaction to the application to the outpatient
clinic was longer in beekeepers than nonbeekeepers, the
difference was not statistically significant (12 [0.25–24]
vs. 10.5 [0.5–24]; p = 0.85). Apis Mellifera positivity was
significantly higher in prick (p = 0.001), and specific IgE
(p = 0.005) results in beekeepers. The double-positivity
rate was higher in beekeepers, and a significant difference
was found between those who are nonbeekeepers (77% vs.
50%; p = 0.042).
In 62 patients who knew the culprit insect in the first
reaction, allergic sensitivity was demonstrated by at least
one method and immunotherapy was initiated with the
same species. In 6 of 11 patients who did not know the
type of the culprit insect, only sensitization to the Vespula
was detected, and immunotherapy was started with the
detected bee venom. Of the 5 patients who did not know
the type of culprit insect, 3 had double sensitization
with skin prick and mono sensitization with specific
IgE. Immunotherapy was initiated in these patients with
venom type positive for both skin prick and specific IgE
(2 patients Vespula, 1 patient Apis Mellifera). Sensitivity
to both bee venom with skin prick and specific IgE was
detected in 2 patients. Since the Vespula had specific IgE
5+ (64 kU/L) and Apis Mellifera specific IgE 1 + (0.58
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kU/L), immunotherapy was started with Vespula in one
of these patients. Venom components were studied in the
other patient. Immunotherapy with Vespula was started in
the patient who was found to be Api m1: negative, Ves v1:
negative, Ves v5: positive on component analysis of venom.
Venom components were studied because one patient
had a history of reaction after a bee sting with both honey
bee and Vespula and had double sensitization with the
SPT. As Api m1: positive, Ves v1: positive, and Ves v5:
positive on component analysis of venom, VIT was started
with both venoms since sensitivity to both venom major
allergens was detected (Figure 2).
Apis VIT was started for 38 patients, Vespula VIT
was started for 34 patients, and 1 patient was started
immunotherapy with both Apis Mellifera and Vespula. Six
(15.7%) of 38 patients who started Apis VIT completed
5-year VIT, and 19 (50%) patients are continuing their
immunotherapy. Three (0.08%) of 34 patients who started

Vespula VIT completed 5 years of VIT, and 25 (73.5%)
patients are continuing their immunotherapy. In 4 patients,
VIT could not be achieved despite dose reduction and
resumption of VIT due to built-up or maintenance phase
reactions (3 patients for Apis VIT; 1 patient for Vespula
VIT). In 15 patients, although the importance of VIT was
explained, VIT was terminated according to the patients’
requests.
VITs of 44 patients who underwent Apis and Vespula
VIT continue without any problem and have not yet
completed 5 years (Figure 3).
3.1. Correlation between SPT and reaction severity
There was no correlation between the severity of the first
reaction and the Apis Mellifera prick diameter in patients
who underwent VIT (p = 0.643; r = –0.056). There was
no correlation between the severity of the first reaction
and the diameter of the Vespula prick in patients who
underwent VIT (p = 0.462; r = 0.089).

Figure 2. IT type of mono-sensitized and double-sensitized patients.
* Monosensitization was detected in both skin prick and specific IgE in four of six patients sIgE: specific immunoglobulin E. One patient
was monosensitize with spesific IgE and double negative with skin prick test. One patient was monosensitize with skin prick test and
double negative with spesific IgE.
** vespula spesific IgE: 64 kU/L, apis mellifera spesific IgE: 0.58 kU/L

1226

PAÇACI ÇETİN et al. / Turk J Med Sci
Table 1. Patients’ characteristics.
Patients
n = 73
Age ± SD (years)
Gender; female (%)
Culprit insect type in the first reaction; n (%)
Apis Mellifera
Vespula spp.
Unknown
Time elapsed after the first reaction; median month (IQR)
First reaction grade; n (%)
Grade 1
Grade 2
Grade 3
Grade 4
Beekeeping; n (%)
Prick A. Mellifera positivity; n (%)
Prick A. Mellifera; median longest diameter (IQR) (mm)
Prick Vespula positivity; n (%)
Prick Vespula; median longest diameter (IQR)mm
sIgE Apis positivity (n = 64) n (%)
sIgE Vespula positivity (n = 62) n (%)
Double-positives based on Prick results; n (%)
Double-positives based on sIgE result; n (%)
Double-positives by any method; n (%)
Blood types AB0 (n = 66)
A
B
AB
0
Blood types Rh (n = 66)
Positive
Negative
The type of IT; n (%)
Apis mellifera
Vespula spp
Apis mellifera + Vespula spp

43 ± 12.9
38 (52)
38 (52.1)
24 (32.9)
11 (15.1)
12 (0.5–24)
6 (8.2)
19 (26)
28 (38.4)
20 (27.4)
17 (23.3)
48 (65.7)
3 (0–5)
51 (69.8)
3 (0–4)
38 (59)
45 (72.5)
29 (40)
26 (36)
41 (56)
31
9
5
21
60
6
38 (52.2)
34 (46.5)
1 (1.3)

sIgE: specific IgE, IT: immunotherapy, IQR: interquartile range

3.2. Reaction severity across blood types
Blood groups of 66 of the patients who received VIT were
taken. The blood type of 31 patients was A, the blood type of
9 patients was B, the blood type of 5 patients was AB, and the
blood type of 21 patients was 0. Sixty patients were Rh +, 6
patients were Rh -.
There was no difference between ABO blood groups
in terms of reaction severity (p = 0.394) (Table 3). There

was no difference in reaction severity between Rh blood
groups (p = 0.533) (Table 4).
3.3. VIT and systemic reactions
All patients to whom we applied VIT received a single
dose of antihistamine 1 h before VIT in the build-up
phase. During the build-up phase, 60 systemic reactions
due to VIT were observed in 23 different patients. Of
these 23 patients, 13 patients had immunotherapy with
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Apis Mellifera (24 reactions in total) and 10 patients with
Vespula (36 reactions in total). In the built-up phase, no
reaction was observed in any of the 5 patients stung by
the bee species who were administered immunotherapy.
During the maintenance phase, a total of 33 systemic
reactions were observed in 11 different patients. Of
these 11 patients, 8 patients were in the Apis Mellifera
(20 reactions) and 3 patients were in the Vespula (13
reactions) group. The most common systemic reactions
are dyspnea and numbness in the hand and foot. Other
systemic reactions are nausea, palpitations, dizziness,
pruritus, uvula edema, and hypotension, respectively. The
demographic and characteristic data of these patients are
summarized in Table 5. Two of these patients had high
levels of tryptase, none of them have any autoimmune
disease, only one patient used beta-blocker, seven patients
were polysensitized. In the maintenance phase, no reaction
was observed in 13 of 18 patients who were injected with
bees, who received immunotherapy, and 5 patients who
developed anaphylaxis (Figure 4).
3.4. Omalizumab and VIT
VIT was continued with omalizumab treatment in 2
patients who experienced a systemic reaction during the
bee VIT build-up and could not tolerate VIT during the
step-up process after dose reduction. Immunotherapy

of the first patient was discontinued due to continuing
systemic reactions despite dose increase under
omalizumab treatment. The patient did not accept further
diagnostic tests for mastocytosis. IT was applied under
omalizumab due to the development of anaphylaxis
during the dose increase in the other patient. In this way,
the immunotherapy of the patient could be increased to
the maintenance phase dose. Anaphylaxis developed at
the third maintenance dose in the patient who received
two maintenance doses without any problem without
omalizumab. IT was discontinued when it was decided
that the desired immunomodulatory efficacy could not be
achieved due to the systemic reaction at the maintenance
dose after omalizumab was discontinued [14]. Venom
immunotherapy protocols administered to the patient
with omalizumab are summarized in Table 6.
3.5. High dose VIT
High dose VIT was given with Apis Mellifera in 3 patients
and Vespula in 1 patient (150,000 U), as a systemic reaction
developed during VIT during the maintenance or the
systemic reactions after a bee sting with the bee species in
which VIT was performed during the maintenance. While
three of these patients continued with the VIT without
any problem, VIT of one patient was terminated due to
frequent reactions with high doses.

Table 2. General characteristics of patients with and without beekeeping.
Beekeepers
n = 17

Nonbeekeepers
n = 56

P

Age ± SD

47.2 ± 10.3

41.8 ± 13.5

0.135

Gender; female (%)

4 (24)

34 (61)

0.007

Apis melifera

15 (88)

23 (41)

Vespula spp.

1 (6)

23 (41)

Unknown

1 (6)

10 (18)

Time elapsed after first reaction; month (IQR)

12 (0.25–24)

10.5 (0.5–24)

Grade 1

4 (24)

2 (4)

Grade 2

2 (12)

17 (30)

Grade 3

6 (35)

22 (39)

Grade 4

5 (29)

15 (27)

Apis Mellifera

17 (100)

31 (55)

0.001

Vespula spp

9 (53)

42 (75)

0.115

Apis Mellifera

15 (88)

23 (41)

0.005

Vespula Spp

9 (53)

36 (64)

0.089

Double-positives by any method; n (%)

13 (77)

28 (50)

0.042

Culprit insect type in the first reaction (%)
0.003
0.85

First reaction grade; n (%)

0.043

Prick positivity; n (%)

sIgE positivity; n (%)
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Table 3. Comparison of prick test results between different ABO blood types.
A (n = 31)

B (n = 9)

AB (n = 5)

0 (n = 21)

p

Median Apis Mellifera prick diameter (mm)

3 (0–5.25)

0 (0–6)

3 (1–4.5)

3 (0–5)

0.89

Median Vespula diameter (mm)

4 (3–4.5)

3 (1.5–4)

0 (0–4.5)

3 (0–5.5)

0.568

mm: millimeters
Table 4. Comparison of prick test results between two Rh blood types.
Rh+ (n = 60)

Rh- (n = 6)

p

Median Apis Mellifera prick diameter (mm)

3 (0–5)

4 (1.5–5.25)

0.65

Median Vespula prick diameter (mm)

3 (2.25–4.25)

1.5 (0–4.75)

0.372

mm: millimeters

Figure 3. Treatment processes of patients receiving IT.
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Table 5. Demographic and characteristic data of patients who experienced systemic reactions in the maintenance phase.
Patient

Serum Tryptase Chronic Disease

Autoimmune Disease Beta Blocker Ace INHB Polysensitization
+
+
-

High Dose

Patient 1

>11.4 μg/L

Patient 2

Normal

Patient 3

Normal

-

-

-

-

+

+

Patient 4

>11.4 μg/L

-

-

-

-

+

-

Patient 5

Normal
(2.7 μg/L)

-

-

-

-

+

+

Patient 6

-

-

-

-

-

+

-

Patient 7

Normal
(4.36 μg/L)

-

-

-

-

-

+

Patient 8

-

-

-

-

-

+

+

Patient 9

Normal
(8.6 μg/L)

HT

-

+

-

-

-

Patient 10

-

-

-

-

-

-

-

Patient 11

-

-

-

-

-

-

-

Hepatitis B

ACE INHB: Angiotensin-converting-enzyme inhibitors, HT: hypertension

Figure 4. IT-related systemic reactions. VIT: venom immunotherapy

1230

-

PAÇACI ÇETİN et al. / Turk J Med Sci
Table 6. Venom immunotherapy protocols with omalizumab.
Patient 1

Patient 2

Systemic reaction with 4. vial 0.8 cc dose of immunotherapy Systemic reaction with 4. vial 0.6 cc dose of immunotherapy
week 0: 150 mg omalizumab

week 0: 150 mg omalizumab

week 1: 4. vial 0.3 cc

week 2: 4. vial 0.4 cc (with 150 mg omalizumab before 4 h), no reaction

week 2: 4. vial 0.4 cc (with 150 mg omalizumab before 4 h),
no reaction

week 3: 4. vial 0.5 cc, no reaction

week 3: 4. vial 0.5 cc, no reaction

week 4: 4. vial 0.6 cc (with 150 mg omalizumab before 4 h), no reaction

week 4: 4. vial 0.6 cc (with 150 mg omalizumab before 4 h),
no reaction

week 5: 4. vial 0.7 cc, no reaction
week 6: 4. vial 0.8 cc (with 150 mg omalizumab before 4 hours), no reaction
week 7: 4. vial 0.9 cc, no reaction
week 8: 4. vial 1 cc (with 150 mg omalizumab before 4 hours), no reaction

week 5: 4. vial 0.7 cc, systemic reaction with chills,
hypotension, cough and dyspnea

week 10: 4. vial 1 cc, no reaction
week 13: 4. vial 1 cc, no reaction
week 17: 4. vial 1 cc, systemic reaction with facial erythema and itching,
nausea, uvula edema and dyspnea
week 19: 4. vial 0.4 cc (with 150 mg omalizumab before 4 h), systemic reaction
with uvula edema, dyspnea, facial erythema and itching

4. Discussion
In our study, it was seen that Apis Mellifera VIT was the
majority of those who had VIT, and those who had a history
of systemic reactions with bees had a long time between the
application of bee VIT. Double positive sensitization was
detected in DPT and/or sIgE in about half of the patients.
There was no correlation between skin prick, specific IgE,
and blood types of VIT patients and their reaction severity
in the history. The most common systemic reaction was
experienced with the Vespula VIT. It was observed that
the use of omalizumab together in patients who could not
tolerate VIT was not very effective in immune switching.
High-dose VIT could be tolerated. With this study, the
characteristics of our patient cohort receiving bee VIT
and the difficulties and solutions encountered before and
during VIT were revealed.
The family Apidae consists of the Apis mellifera
(honeybees) and the Bombus (bumble-bees) species. The
family Vespidae consists of the Vespinae [three genera:
Vespa (hornets), Dolicho-Vespula (wasps), Vespula
(wasps or yellow jackets)] and the Polistinae (single genus:
Polistes, wasps) subfamilies [4]. Sting reactions in the
entire Mediterranean area are most frequently caused by
Vespula, Polistes, and Apis Mellifera. In our study, VIT was
applied more with Apis Mellifera. Excessive beekeeping in
our country and our region causes us to encounter more
systemic reactions seen with honey bees. Before VIT is

initiated in a person with a history of systemic reaction
with bees, sensitization must be demonstrated by at least
one skin prick, specific IgE, and/or basophil activation
tests. In our study, it has been shown that the time from
systemic reaction to sensitization with bees is very long.
Although all of our patients applied to the emergency
department after these reactions, their application to the
allergy outpatient clinic was too late, and recurrent stings
might occur during this time. In our patient group, this
period was longer in beekeepers than in nonbeekeepers.
For this reason, we think that social awareness should be
raised to increase awareness on this issue to make these
periods earlier.
Sensitization to both Apis Mellifera and Vespula
venom is common in people with insect venom allergies. It
is difficult to determine whether this is due to true double
sensitization or cross-reactivity. It is essential to choose the
proper venom preparation to get the desired benefit from
VIT. Double positivity is common between Vespula and
Apis Mellifera in patients who experience systemic allergic
reactions after a bee sting [15,16]. The major cross-reactive
component between these two groups is hyaluronidase
[4,17,18]. The diagnostic tests available are inadequate
to distinguish between asymptomatic sensitization and
clinically significant allergy [3]. There is no common
consensus on the continuation of IT single or double in
individuals with dual sensitization. In our study, 56% of

1231

PAÇACI ÇETİN et al. / Turk J Med Sci
patients had double sensitization. This ratio is between
30%–59% in previous studies [10,19]. Regarding the
subject, in the algorithm developed by Johanna et al., in
cases where the culprit insect is known, even if double
sensitization is detected in skin prick and/or serological
test results, a single VIT can be performed with the culprit
type. In cases where the culprit insect is unknown, if there
is a significant difference between the skin prick and
serological tests and sensitization against a single venom
is stronger, it recommends performing a single VIT again
[20]. In our clinic, similar to the algorithm developed by
Johanna et al., in cases where the culprit insect is known,
we do a single VIT with the culprit type even if double
sensitization is detected in the skin prick and/or serological
test results. In cases where the culprit insect is not known,
if there is a significant difference between skin prick and
serological tests and sensitization against single venom is
stronger, we do single VIT again. However, in cases where
the culprit insect is unknown, we work with components
if there is no significant difference between the skin prick
and serological tests. Whichever bee species-specific major
component is positive, we apply VIT to patients with that
species. If the major component of both bee species is
positive, we apply VIT to both of them.
Another issue that is curious about bee venom allergies is
whether there is a relationship between SPT and/or specific
IgE results and the severity of the systemic reaction. In a
study by Annila et al., no relationship was found between
the degree of systemic reaction experienced in the past in
beekeepers and the serum levels of Apis Mellifera specific
IgE antibodies. SPT with Apis Mellifera was significantly
higher in 31 patients who had systemic reactions than
beekeepers who had local or no reactions (p < 0.05) [21]. In
a study investigating risk factors for systemic reactions in
patients with venom allergy, no significant relationship was
found between the amount of both Vespula and Apis sIgE
and SPT and the severity of systemic reactions [22]. In the
study conducted by Warrington et al., no correlation was
found between the severity of the clinical reaction and the
degree of skin test reactivity or sIgE levels in the analysis of
36 patients with sudden hypersensitivity reactions to bee
venom [23]. In our study, too, no correlation was found
between the severity of systemic reactions and the results
of SPT and sIgE. When we questioned whether there was
a relationship between blood groups and reaction severity,
we found no difference between AB0 blood groups in
terms of reaction severity since the relationship had never
been examined before.
VIT with the honey bee is an independent predictor for
the high risk of systemic reactions during immunotherapy
[24,25]. In our study, in line with previous information, the
number of patients who experienced systemic reactions
was higher in the Apis Mellifera VIT group. Omalizumab
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has been used as an alternative agent to achieve the
maintenance dose in patients with frequent systemic
reactions during VIT [26,27]. However, it was observed
that the use of omalizumab together in patients who
could not tolerate VIT was not very effective in immune
switching. In a patient who experienced a systemic
reaction during VIT dose increase, monthly omalizumab
treatment was given 6 months before VIT, then VIT was
restarted, but VIT could not be continued due to recurrent
systemic reactions [28]. In our study, omalizumab was
given to two patients who could not tolerate VIT, but these
patients continued to have systemic reactions with VIT
after omalizumab was discontinued [14]. This suggests
that omalizumab has a strong premedication effect but
not an immunomodulatory effect on VIT. Failure of VIT
and omalizumab combination therapy may be caused by
the lack of standardization regarding omalizumab dose,
administration interval, administration time, and how
long before VIT is restarted.
Increasing the dose with the rush and ultra-rush
protocols may increase the chance of success in patients
with maintenance reactions, but on the other hand, there
is a potential to increase the risk of VIT side effects with
these protocols. In addition, VIT cannot be performed in
these protocols due to the lack of aqueous extracts in our
country.
In some patients, the immune-modifying effect of VIT
cannot be achieved with a routine 100 µg maintenance
dose, and higher doses are required. The maintenance
dose can be increased to 200 µg in patients who develop
systemic allergic reactions after a bee sting or during
VIT [3]. This dose can be well tolerated by patients [29].
However, in our clinical practice, we increase the dose
up to 150 µg (150,000 U), if there is a systemic reaction
with this dose, we plan to increase it to 200 µg (200,000
U). In our study, the high dose (150 µg) was increased
in a total of four patients; although three of the patients
tolerated it well and had no reaction, immunotherapy was
discontinued due to the persistence of systemic reactions
in one of them.
One of the study’s limitations is that our study is
retrospective, and the number of patients is partially
low. Especially the number of patients who developed
reactions during VIT maintenance and switched to highdose maintenance treatment and the number of patients
who developed built-up systemic reactions and continued
VIT with omalizumab is quite limited. However, we think
that these results will contribute to clinicians’ management
of patients in situations where these problems are
encountered.
One of the limitations of the study is that it is difficult
to rule out double sensitization because component-based
tests were not performed in all patients. However, in patients
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with double sensitivity and whose history is unclear, the
component was studied by explaining its importance to the
patient. On the other hand, VIT was planned according to
the anamnesis for double positivity, which clearly describes
the stinger and the reaction (e.g., a beekeeper who knows
bees well and knows that stung by honeybees).
A final limitation is the absence of all components
to which the patient may be sensitized in venom
immunotherapy extracts. One of the advantages of
component-based tests is that it can be determined
whether there is sensitivity to components that are not
included in the venom IT contents. In cases where VIT
fails, the components that are not included in the extracts
can also be studied to reveal the reason for the failure.
In conclusion, although systemic reactions were seen
more in Apis Mellifera VIT patients, most patients could
tolerate VIT. Double positivity before VIT is one of the most
common difficulties before immunotherapy. This problem
can be solved with appropriate algorithms according to

whether the suspected allergen is known or not, SPT/sIgE
results, and components. One of the common difficulties
in the VIT process is the systemic reactions that occur
secondary to VIT. A maintenance dose increase should be
considered for those who have reacted in the maintenance
phase. However, adding omalizumab to VIT does not
seem to be a permanent solution in patients who develop a
built-up severe systemic reaction. VIT cannot be tolerated,
although the dose is decreased and increased gradually.
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